Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of VIT-2763 in non-transfusion-dependent beta thalassemia
MOH_2020-03-31_008820Phase 2Not yet recruiting
- Sponsor
- CSL Vifor
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in beta thalassemia comparing Placebo with VIT-2763 (2 arms). Primary endpoint: Safety and tolerability of VIT-2763. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
vamifeport
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on MOH_2020-03-31_008820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-31_008820.